Valeant defended its relationship with a specialty pharmacy that distributes some of its drugs, following a critical report by a short-selling research firm that wiped as much as $20 billion from its market value on Wednesday.
from WSJ.com: US Business http://ift.tt/1GiU0en
via IFTTT
No comments:
Post a Comment